Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA/PhRMA Task Force To Assess QT Risk By Preclinical Markers

Executive Summary

FDA and the Pharmaceutical Research & Manufacturers of America are forming a joint task force to define a preclinical threshold to serve as a predictor for the risk of drug-associated QT prolongation.

You may also be interested in...



Searching For Surrogate Endpoints Requires Teamwork

Discussions between FDA and researchers during a workshop on the fatty liver conditions NAFLD/NASH clarified the status of potential surrogate endpoints for clinical trials, but indicated that much work remains to be done to ready the various options for use – and that will likely need to be a joint effort.

Glaxo Withdraws Raxar Following Seven Fatal Cardiovascular AEs

Glaxo Wellcome is withdrawing the quinolone antibiotic Raxar (grepafloxacin) from the worldwide markets after receiving a total of seven reports of cardiovascular event-related fatalities associated with use of the drug.

Glaxo Withdraws Raxar Following Seven Fatal Cardiovascular AEs

Glaxo Wellcome is withdrawing the quinolone antibiotic Raxar (grepafloxacin) from the worldwide markets after receiving a total of seven reports of cardiovascular event-related fatalities associated with use of the drug.

UsernamePublicRestriction

Register

LL1126230

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel